Filing Flows › TransMedics Group (TMDX) › Guidance & outlook

TransMedics Group (TMDX) guidance and outlook

TransMedics Group (TMDX) raised its guidance on Nov 5, 2026: Revenue $764M–$774M for FY2026. TransMedics Group's 10-Q filed Nov 5, 2026 makes 25 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• We expect our operating and capital expenditures will continue to increase as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets.
• Because of the numerous risks and uncertainties associated with product development, commercialization and regulations of our industry, we are unable to accurately predict the timing or amount of increased expenses or if we will be able to maintain profitability.
• If we are unable to raise capital or enter into such agreements as, and when, needed, we will have to delay, scale back or discontinue the further development and commercialization efforts of one or more of our products, or may be forced to terminate our operations.
• We expect the investment in PAD Aviation will enable us to expand our aviation transportation capabilities and support the future development of our organ retrieval and logistics services in Europe.
• Unfavorable economic conditions have and could continue to result in a variety of risks to our business, including impacts on demand and pricing for our products and pricing and availability of raw materials and components for our products, which could make it difficult to forecast our inventory needs and financial results.
• Following the investment in PAD Aviation, we anticipate expanding our transplant logistics services in Europe.
• We expect PAD Aviation to continue generating revenue from these operations, which will be recorded within service revenue.
• We expect that our revenue will increase over the long term as a result of the continued growth of the NOP in the United States.
• We also expect that our revenue will increase over the long term as a result of anticipated growth in non-U.S. sales if national healthcare systems begin to reimburse transplant centers for the use of the OCS, if transplant centers utilize the OCS in more transplant cases and if more transplant centers adopt the OCS in their programs.
• While we expect our revenue to increase over the long term, revenue from sales may fluctuate from quarter to quarter as the timing of organ transplant procedures is generally unpredictable, and we have observed periodic fluctuations in the availability of donor organs and transplant center surgeons, which impacts the volume of transplants.
• We expect that overall cost of revenue will increase or decrease in absolute dollars primarily as, and to the extent that, our revenue increases or decreases.
• We expect that the cost of net product revenue as a percentage of net product revenue will moderately decrease and gross margin and gross profit will moderately increase over the long term as our sales and production volumes increase and our cost per unit of our OCS disposable sets decreases due to economies of scale, our product enhancements and improved manufacturing efficiency.

TransMedics Group's latest quarter

Questions

Did TransMedics Group raise or lower its guidance?

TransMedics Group (TMDX) raised its guidance on Nov 5, 2026: Revenue $764M–$774M for FY2026.

What does TransMedics Group expect?

We expect our operating and capital expenditures will continue to increase as we focus on growing commercial sales of our products in both the United States and select non-U.S. markets. Because of the numerous risks and uncertainties associated with product development, commercialization and regulations of our industry, we are unable to accurately predict the timing or amount of increased expenses or if we will be able to maintain profitability. If we are unable to raise capital or enter into such agreements as, and when, needed, we will have to delay, scale back or discontinue the further dev

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.